ReviewCancers2021
Resistance to Cell Death in Mucinous Colorectal Cancer-A Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Impact of Neoadjuvant Chemotherapy on Prognosis of Patients with Mucinous Gastric Adenocarcinoma: A Propensity Score Matching Study.Annals of surgical oncology · 2026Article
- Article
- The Power of MUC2 in Mucinous Adenocarcinomas.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Review
- Serine-arginine protein kinase 1 (SRPK1) is under-expressed in mucinous colorectal cancer, and may mediate resistance to oxaliplatin.The pharmacogenomics journal · 2025Article
- Acellular mucin in neoplastic and non-neoplastic conditions of the lower gastrointestinal tract.World journal of gastrointestinal surgery · 2025Review
- Mucinous rectal adenocarcinoma recurrence: A case report and literature review.Radiology case reports · 2025Article
- The Influence of Mucinous Histology on the Prognosis of Stage II and III Colorectal Cancers.Medicina (Kaunas, Lithuania) · 2025Article
- Comparative Outcomes of Neo-Adjuvant Chemo-Radiotherapy in Stage II and III Mucinous versus Non-Mucinous Rectal Adenocarcinoma: A Retrospective Study.Cancer management and research · 2025Article
- Article
- Construction and validation of prognostic model for colorectal mucinous adenocarcinoma patients and identification of a new prognosis related geneTranslational cancer research · 2024Article
- Crosstalk of cell death pathways unveils an autophagy-related gene AOC3 as a critical prognostic marker in colorectal cancer.Communications biology · 2024Article
- Identification and validation of a novel six-gene signature based on mucinous adenocarcinoma-related gene molecular typing in colorectal cancer.Discover oncology · 2024Article
- Recursive partitioning staging system based on the log odds of the negative lymph node/T stage ratio in colon mucinous adenocarcinoma.Frontiers in immunology · 2024Article
- Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Local recurrence after successful endoscopic submucosal dissection for rectal mucinous mucosal adenocarcinoma: A case report.World journal of gastrointestinal oncology · 2023Article
- Bromelain and acetylcysteine (BromAcAmerican journal of cancer research · 2023Review
- Article
- The Natural Compound Hydrophobic Usnic Acid and Hydrophilic Potassium Usnate Derivative: Applications and Comparisons.Molecules (Basel, Switzerland) · 2021Review
- Identification of Circular RNAs Associated With Chemoresistance in Colorectal Cancer.Frontiers in genetics · 2021Article
- Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mucinous colorectal cancer (CRC) is estimated to occur in approximately 10-15% of CRC cases and is characterized by abundant extracellular mucin. Mucinous CRC is frequently associated with resistance to apoptosis. Inferior prognosis is observed in mucinous CRC, particularly in rectal cancer and metastatic cases. Mucins are heavily glycosylated secretory or transmembrane proteins that participate in protection of the colonic epithelium. MUC2 overexpression is a hallmark of mucinous CRCs. Mucinous CRC is associated with KRAS and BRAF mutation, microsatellite instability and the CpG island methylator phenotype. Mutations of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.